The purpose of this study was to evaluate the cost-effectiveness of adjuvant trastuzumab treatment of HER2+ early stage breast cancer (ESBC) patients from the perspective of the Belgian health care authorities. METHODS: An existing Markov model, comparing 1 year adjuvant trastuzumab treatment to current therapy and simulating disease progression over a lifetime perspective, was adapted to the Belgian context. The model included 5 Markov states (disease free survival, recurrence, metastasis, cardiac side effects, death) and three temporary 1-cycle states preceding respectively the aforementioned recurrence, metastasis and cardiac side effects states. Transition probabilities were obtained from the EU registration trial (HERA). Health benefits were expressed in quality-adjusted life years (QALY) gained, future benefits were discounted at 1.5%. QALY-weights were obtained from published literature. Costs were calculated from the perspective of the Belgian health care budget (year 2005), future costs were discounted at 3%. Costs were obtained from the IMS Belgian Hospital Disease Database (longitudinal database, representative panel of 37 hospitals), from an expert opinion analysis (6 Belgian oncology centers), and from official data sources and published literature. A deterministic incremental cost-effectiveness ratio (ICER) was calculated for 5 different age categories (<50, 50-59, 60-69, 70-79 and Ն80 years). Confidence intervals (95% CI) were estimated by probabilistic sensitivity analyses. Based on the estimated Belgian age distribution of HER2+ ESBC patients, an overall deterministic ICER for the Belgian population of treatment eligible patients was calculated. RESULTS: The ICER for age categories <50, 50-59, 60-69, 70-79 and Ն80 years was estimated at respectively €6,520 (95% CI: €3,704-€10,350), €8,363 (95% CI: €4,793-€13,436), €12,343 (95% CI: €6,636-€20,224), €24,997 (95% CI: €13,708-€42,908) and €96,150 (95% CI: €53,944-€206,007) per QALY gained. The ICER for the total Belgian population of treatment eligible patients was estimated at €10,315 per QALY gained. CONCLUSION: Adjuvant trastuzumab treatment of HER2+ ESBC patients is predicted to be cost-effective from the perspective of the Belgian health care payer. Nab-paclitaxel's per cycle price was assumed to equal docetaxel's. Costs and benefits were discounted at 3.5%. Probabilistic sensitivity analyses were conducted. RESULTS: Compared to Pac-1w, docetaxel yields higher mean health benefits (2.01 vs. 1.73 life years (LYs) and 1.18 vs. 1.03 quality-adjusted life-years (QALYs)) and costs less than the generic paclitaxel (Յ13,518 vs. Յ15,008) therefore permits the NHS to save Յ5400/LY and Յ9800/QALY. Against Nab-paclitaxel, docetaxel produced higher LYs (2.01 vs. 1.62) and QALYs (1.18 vs. 0.96) but at a slightly higher cost (Յ13,518 vs. Յ11,640). Docetaxel had an incremental costeffectiveness ratio of Յ4900/LYG and Յ8600/QALY against Nabpaclitaxel. Given the indirect nature of this analysis, ICERs rely on many assumptions and are sensitive to hazard ratios and to the price of treatments. Confidence intervals around the ICERs are consequently high. CONCLUSION: Based on current evidence docetaxel is cost-saving compared to generic pac-1w, which is used but not approved in the UK, and cost effective compared to Abraxane. Data from ongoing head-to-head clinical studies will be necessary to reduce the wide confidence intervals. To evaluate the cost effectiveness of maintenance rituximab therapy in the treatment of relapsed/refractory follicular NHL compared to observation alone. METHODS: A health state transition model with 3 health states (progression-free, progressive disease and death) was created utilising the Kaplan Meier progression-free and overall survival data from the EORTC20981 registration trial for the first 24 months of the model. A Weibull parametric function was then used to extrapolate survival for the remaining lifetime time-horizon of the model, selection of the parametric function was based on goodness of fit, relative to alternative parametric functions. The assumed treatment effect of rituximab was limited to 5 years in the model thereafter rituximab patients subsequently had a monthly risk of death and disease progression equivalent to the observation group. Patient characteristics were assumed equivalent to the EORTC20981 study. QALYs were derived using utility scores from a UK survey of over 200 follicular lymphoma patients using the EQ-5D instrument, valued from the societal perspective. Post protocol treatments were included, estimated directly from the EORTC20981 study, routine patient monitoring, drug administration and adverse event costs were also included. RESULTS: Rituximab maintenance was associated with an additional 0.89 QALYs compared to the observation arm and total costs were Յ6886 higher in the maintenance arm. The
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Nab-paclitaxel's per cycle price was assumed to equal docetaxel's. Costs and benefits were discounted at 3.5%. Probabilistic sensitivity analyses were conducted. RESULTS: Compared to Pac-1w, docetaxel yields higher mean health benefits (2.01 vs. 1.73 life years (LYs) and 1.18 vs. 1.03 quality-adjusted life-years (QALYs)) and costs less than the generic paclitaxel (Յ13,518 vs. Յ15,008) therefore permits the NHS to save Յ5400/LY and Յ9800/QALY. Against Nab-paclitaxel, docetaxel produced higher LYs (2.01 vs. 1.62) and QALYs (1.18 vs. 0.96) but at a slightly higher cost (Յ13,518 vs. Յ11,640). Docetaxel had an incremental costeffectiveness ratio of Յ4900/LYG and Յ8600/QALY against Nabpaclitaxel. Given the indirect nature of this analysis, ICERs rely on many assumptions and are sensitive to hazard ratios and to the price of treatments. Confidence intervals around the ICERs are consequently high. CONCLUSION: Based on current evidence docetaxel is cost-saving compared to generic pac-1w, which is used but not approved in the UK, and cost effective compared to Abraxane. Data from ongoing head-to-head clinical studies will be necessary to reduce the wide confidence intervals. To evaluate the cost effectiveness of maintenance rituximab therapy in the treatment of relapsed/refractory follicular NHL compared to observation alone. METHODS: A health state transition model with 3 health states (progression-free, progressive disease and death) was created utilising the Kaplan Meier progression-free and overall survival data from the EORTC20981 registration trial for the first 24 months of the model. A Weibull parametric function was then used to extrapolate survival for the remaining lifetime time-horizon of the model, selection of the parametric function was based on goodness of fit, relative to alternative parametric functions. The assumed treatment effect of rituximab was limited to 5 years in the model thereafter rituximab patients subsequently had a monthly risk of death and disease progression equivalent to the observation group. Patient characteristics were assumed equivalent to the EORTC20981 study. QALYs were derived using utility scores from a UK survey of over 200 follicular lymphoma patients using the EQ-5D instrument, valued from the societal perspective. Post protocol treatments were included, estimated directly from the EORTC20981 study, routine patient monitoring, drug administration and adverse event costs were also included. RESULTS: Rituximab maintenance was associated with an additional 0.89 QALYs compared to the observation arm and total costs were Յ6886 higher in the maintenance arm. The
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